Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

June 5, 2020

Study Completion Date

July 15, 2020

Conditions
AnemiaDialysis-dependent Chronic Kidney Disease
Interventions
DRUG

Vadadustat

Vadadustat Tablets 150 mg

DRUG

Epoetin Alfa

Epoetin Alfa

DRUG

Vadadustat TIW

Oral Vadadustat

Trial Locations (41)

10461

Research Site, The Bronx

23320

Research Site, Chesapeake

23510

Research Site, Norfolk

28401

Research Site, Wilmington

28801

Research Site, Asheville

30458

Research Site, Statesboro

30909

Research Site, Augusta

32789

Research Site, Winter Park

33024

Research Site, Hollywood

33126

Research Site, Miami

33134

Research Site, Coral Gables

Research Site, Miami

33150

Research Site, Miami

33607

Research Site, Tampa

33614

Research Site, Tampa

44718

Research Site, Canton

48066

Research Site, Roseville

53226

Research Site, Wauwatosa

55404

Research Site #1, Minneapolis

Research Site #2, Minneapolis

64111

Research Site, Kansas City

73116

Research Site, Oklahoma City

77004

Research Site, Houston

78229

Research Site, San Antonio

78258

Research Site, San Antonio

79915

Research Site, El Paso

80230

Research Site, Denver

89107

Research Site, Las Vegas

90022

Research Site, Los Angeles

91324

Research Site, Northridge

91344

Research Site, Granada Hills

91356

Research Site, Tarzana

91773

Research Site #1, San Dimas

Research Site #2, San Dimas

91776

Research Site, San Gabriel

92394

Research Site, Victorville

92501

Research Site, Riverside

93720

Research Site, Fresno

95688

Research Site, Vacaville

06606

Research Site, Bridgeport

06762

Research Site, Hartford

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT03799627 - Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa | Biotech Hunter | Biotech Hunter